Piper Sandler Rates Oruka Therapeutics Overweight with $75 Price Target

Piper Sandler gives Oruka Therapeutics an Overweight rating, highlighting its unique antibody portfolio, ORKA-001 validation, and a promising 2026 catalyst-rich year.